MONARCC

The aim of this study is to investigate the activity of anti-EGFR monotherapy, or combined with infusional 5FU, in a molecularly selected, elderly patient population with metastatic colorectal cancer.

Metastatic colorectal cancer is a disease of the elderly. Anti-EGFR antibodies have not been well studied in an elderly patient population unsuited to combination chemotherapy.  The median age in trials involving these agents is 60-65 years. As a result there is an opportunity to investigate the activity of anti-EGFR monotherapy, or combined with “light” chemotherapy in a molecularly selected, hitherto under-investigated but prevalent patient population.

Share

Trial Status

Open

Cancer Type

Colorectal Cancer

If you think this trial is relevant to your situation, please contact your Cancer Specialist to discuss further.

Aim

The aim of this study is to investigate the activity of anti-EGFR monotherapy, or combined with infusional 5FU, in a molecularly selected, elderly patient population with metastatic colorectal cancer.

Summary

Metastatic colorectal cancer is a disease of the elderly. Anti-EGFR antibodies have not been well studied in an elderly patient population unsuited to combination chemotherapy.  The median age in trials involving these agents is 60-65 years.  As a result there is an opportunity to investigate the activity of anti-EGFR monotherapy, or combined with “light” chemotherapy in a molecularly selected, hitherto under-investigated but prevalent patient population.

Participating Centres

New South Wales
NCCI – Coffs Harbour Health Campus
The Tweed Hospital
Nepean Cancer Centre
Queensland
Royal Brisbane and Womens Hospital
Gold Coast Hospital
Princess Alexandra Hospital
Tasmania
Royal Hobart Hospital
Victoria
Monash Medical Centre
Western Health-Sunshine Hospital

Trial Status

Open

Cancer Type

Colorectal Cancer

If you think this clinical trial may be relevant to your patient or to discuss further, please contact the Clinical Trial team.

Protocol Title

A randomised phase 2 study of panitumumab monotherapy and panitumumab plus 5 fluorouracil as first line therapy for RAS and BRAF wild type metastatic colorectal cancer

Aim

The aim of this study is to investigate the activity of anti-EGFR monotherapy, or combined with infusional 5FU, in a molecularly selected, elderly patient population with metastatic colorectal cancer.

Background

Metastatic colorectal cancer is a disease of the elderly. Anti-EGFR antibodies have not been well studied in an elderly patient population unsuited to combination chemotherapy.  The median age in trials involving these agents is 60-65 years.  As a result there is an opportunity to investigate the activity of anti-EGFR monotherapy, or combined with “light” chemotherapy in a molecularly selected, hitherto under-investigated but prevalent patient population.

CLINICAL TRIAL DESIGN

A prospective randomised phase 2 study to assess the activity of panitumumab alone versus panitumumab plus 5FU as first line treatment for RAS wild type elderly patients with metastatic colorectal cancer.

Patients Recruited

Click to access the table and view recruitment data on all AGITG open trials:

Open Trial Recruitment Table

Participating Centres

New South Wales
NCCI – Coffs Harbour Health Campus
The Tweed Hospital
Nepean Cancer Centre
Queensland
Royal Brisbane and Womens Hospital
Gold Coast Hospital
Princess Alexandra Hospital
Tasmania
Royal Hobart Hospital
Victoria
Monash Medical Centre
Western Health-Sunshine Hospital

Contact Email

monarcc@ctc.usyd.edu.au

Principal Investigator

Dr Matthew Burge

More Information

Detailed information will be available shortly on: Australian and New Zealand Clinical Trials Registry

Funding

AGITG Innovation Fund ($100,000)
Alan Bishop Fund ($20,000)